###### Strengths and limitations of this study

-   The study included a large population with four estimated glomerular filtration rate measurements in different time periods, representative of the general population.

-   Data were collected over 10 years.

-   Proteinuria, smoking status and body mass index were not included in the analyses.

-   Using a real-life dataset means that there was an important loss to follow-up due to a combination of mortality and change of general practitioner.

Introduction {#s1}
============

Loss of kidney function due to advanced age is a normal phenomenon. Changes in glomerular filtration rate (GFR) are a consequence of haemodynamic and structural changes, including loss of renal mass.[@R1] In the Flemish part of Belgium, the prevalence of chronic kidney disease (CKD) is estimated at 13% in men and 16% in women.[@R2]

Only a few patients with CKD will progress to end-stage renal disease because most of them will die of other causes such as cardiovascular (CV) disease. Risk factors that contribute to the development of end-stage renal disease are diabetes, high cholesterol, high Low density lipoprotein (LDL), hypertension and female gender.[@R3] However, an estimated GFR (eGFR) persistently (≥3 months) dropping below 60 mL/min/1.73 m^2^ signifies CKD and is associated with a higher risk of complications. In patients with CKD, hospitalisation rates are higher and they have an increased risk of CV disease and death.[@R5] Rapid decline of kidney function is suggested to cause a higher incidence of CV events such as acute myocardial infarction (AMI), heart failure, stroke (cerebrovascular accident (CVA) or TIA (transient ischemic attack (TIA)) and peripheral artery disease.[@R7] The higher CV risk in CKD is often under-recognised and undertreated in primary care.[@R9]

The eGFR slope represents a more dynamic parameter compared with measurements taken at one point.[@R10] A distinction can be made between stable eGFR (±1 mL/min/year) and variable eGFR (±3 or ±5 mL/min/year). In their study on CV health, Shlipak *et al* [@R8] found that especially a rapid decline of eGFR, defined as \>3 mL/min/year, indicates a higher risk of AMI, heart failure and stroke. Another study[@R14] reports a similar correlation between eGFR decline and CV events. These studies add further evidence that changes in eGFR slope can give a worse CV outcome. This could be a relevant parameter for automatically generated CV risk calculations. However, before implementing the eGFR slope in risk calculations, it is essential to analyse its predictive value in population-based data and to analyse the subpopulation that has a strong decline in eGFR over time.

The objective of this study was to determine if the eGFR slope over a 5-year period is related to incident CV events defined as AMI, peripheral arterial disease (PAD), CVA/TIA and acute heart failure (AHF) in the following 5 years in a Flemish general practice population.

Methods {#s2}
=======

Setting {#s2a}
-------

The present study is a retrospective data analysis using the INTEGO databank, which incorporates epidemiological data from more than 100 general practitioners (GPs) residing in the Flemish part of Belgium. In Medidoc, a medical software program, GPs use a coded registration system based on validated algorithms.[@R15] The group of patients that visits the general practice at least once in 1 year is called the 'Yearly Contact Group'. From this database, all patients aged ≥50 years between 1 January 2006 and 31 December 2010 were included in the study. The 5-year period was divided in 10 subperiods of 6 months, that is, '1 January 2006 to 30 June 2006', '1 July 2006 to 31 December 2006' and so forth and only patients with measurements in at least four different time periods were included. The eGFR was calculated with the Modification in renal disease (MDRD) equation (GFR (mL/min/1.73 m^2^)=186×16−1.154×(age)−0.203×(0.742 if female)×(1.212 if black)). With these measurements, we calculated the eGFR slope (mL/min/year) and divided the population into the following subgroups: (−1.00, 1.00) (reference group), (−3.00, --1.00), (−5.00, --3.00), ≤−5.00, (1.00, 3.00) (3.00, 5.00) and ≥5.00 mL/min/1.73 m^2^ per year (mL/min/year). In case a patient had several measurements of creatinine values in the same semester, we included the mean value. We excluded patients of who did not visit their GP after 1 January 2011.

Patient and public involvement {#s2b}
------------------------------

Intego is a long-existing (22 years) database funded by the Flemish government. Patients or their representatives are not involved in the design of this database or research conducted on it.

Outcome {#s2c}
-------

During the follow-up period, between 1 January 2011 and 31 December 2015, CV events described as incident (AMI, ICPC2-code K75 and/or K76), (AHF, K77), Stroke (TIA, CVA, K89; K90) and (PAD, K92) were identified. Patients with prior CV disease were not excluded. Patients who had had no contact with the GP in the follow-up period were censored. We considered the following variables as potential confounders: age, female gender, diabetes (T90), hypertension (K85, K86), baseline kidney function (last value in 5-year period) and history of CV event (codes K75, K76, K77, K89, K90, K92). Patients were censored on the data of their last contact during follow-up.

Statistical analysis {#s2d}
--------------------

All analyses were performed using R software. We analysed the slope of eGFR by using the least-square method and baseline characteristics were measured on 01 January 2011. Next, Cox proportional hazards model was used to evaluate the association between eGFR slope and incidence of CV events. Since the proportional hazards model assumption held, we further calculated the HRs using three different models. Model 1 was the basic model and was adjusted for age and gender. Model 2 was adjusted for age, gender, hypertension, diabetes and CV event history. Lastly, model 3 in addition considered one more covariate, namely baseline kidney function, where we considered the last eGFR measurement before 1 January 2011.

Results {#s3}
=======

The study population is described in [table 1](#T1){ref-type="table"}. Inclusion criteria were met by 19 567 patients and had different eGFR measurements in at least four different time periods. The mean age of this group was 66.1±11.6 years and 52% (10 206) were women. We excluded 465 patients since we were not able to track the last time that they visited a GP. Patients with diabetes or hypertension were slightly more likely to be in the groups with a negative eGFR slope. A history of CV events was more common in the following groups: ≤−5 and (−5 to −3). [Table 1](#T1){ref-type="table"} also shows that 86.0% and 91.9% of the patients in the group with a slope \<−5 and −5 to −3 mL/min/year, respectively had an eGFR \>60 mL/min.

###### 

Baseline characteristics of the study population on 1 January 2011

  eGFR slope (in mL/min/year)                         ≤−5.00        (−5.00, --3.00)   (−3.00, --1.00)   (−1.00, 1.00)   (1.00, 3.00)   (3.00, 5.00)   ≥5.00                                                                                             
  --------------------------------------------------- ------------- ----------------- ----------------- --------------- -------------- -------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------
  Age 50--59                                          299 (18.7)    242 (16.9)        481 (17.1)        653 (17.5)      762 (21.2)     632 (22.9)     959 (26.8)                                                                                        
  Age 60--69                                          383 (24.0)    389 (27.2)        799 (28.4)        1130 (30.3)     1093 (30.4)    917 (33.2)     1157 (32.3)                                                                                       
  Age 70--79                                          473 (30.0)    447 (31.2)        858 (30.5)        1202 (32.2)     1072 (29.8)    792 (28.6)     950 (26.5)                                                                                        
  Age 80+                                             443 (27.8)    355 (24.8)        679 (24.1)        746 (20.0)      671 (18.7)     424 (15.3)     519 (14.5)                                                                                        
  Female gender                                       1048 (65.6)   802 (56.0)        1335 (47.4)       1590 (42.6)     1595 (44.3)    1400 (50.6)    2436 (68.0)                                                                                       
  Diabetes                                            420 (26.3)    302 (21.1)        581 (20.6)        699 (18.7)      604 (16.8)     446 (16.1)     547 (15.3)                                                                                        
  Hypertension                                        719 (45.0)    601 (42.0)        1197 (42.5)       1491 (40.0)     1305 (36.3)    928 (33.6)     1138 (31.7)                                                                                       
  Kidney function                                     First         Last              First             Last            First          Last           First         Last          First         Last          First         Last          First         Last
  Category 1                                          1110 (69.5)   590 (36.9)        828 (57.8)        519 (36.2)      1270 (45.1)    1001 (35.5)    1378 (36.9)   1434 (38.4)   1175 (32.7)   1724(47.9)    878 (31.8)    1834 (66.3)   1610 (44.9)   3267 (91.1)
  Category 2                                          423 (26.5)    604 (37.8)        488 (34.1)        606 (42.3)      1236 (43.9)    1322 (46.9)    1941 (52.0)   1878 (50.3)   2074 (57.6)   1717 (47.7)   1713 (62.0)   895 (32.4)    1838 (51.3)   310 (8.7)
  Category 3a                                         50 (3.1)      214 (13.4)        77 (5.4)          191 (13.3)      225 (8.0)      325 (11.5)     316 (8.5)     325 (8.7)     291 (8.1)     132 (3.7)     149 (5.4)     34 (1.2)      117 (3.3)     6 (0.2)
  Category 3b                                         13 (0.8)      127 (8.0)         31 (2.2)          86 (6.0)        75 (2.7)       129 (4.6)      78 (2.1)      79 (2.1)      52 (1.5)      22 (0.6)      22 (0.8)      2 (0.07)      13 (0.4)      1 (0.03)
  Category 4                                          2 (0.1)       52 (3.3)          9 (0.6)           23 (1.6)        8 (0.3)        33 (1.2)       15 (0.4)      11 (0.3)      4 (0.1)       1 (0.03)      3 (0.1)       0 (0)         4 (0.1)       1 (0.03)
  Category 5                                          0 (0)         11 (0.7)          0 (0)             8 (0.6)         3 (0.1)        7 (0.3)        3 (0.1)       4 (0.1)       2 (0.1)       2 (0.06)      0 (0)         0 (0)         3 0.08)       0 (0)
  \# of patients with CV event in medical history\*   411 (25.7)    358 (25.0)        628 (22.3)        772 (20.7)      622 (17.3)     448 (16.2)     459 (12.8)                                                                                        

Range, (up to and including), through.

Baseline kidney function:

Last=last eGFR measurement in period 1 January 2006 to 31 December 2010.

First=first eGFR measurement in period 1 January 2006 to 31 December 2010.

\*Patients with the following CV events in their medical history: myocardial infarction (AMI, K75 and/or K76), acute heart failure (K77), cerebrovascular event (TIA, CVA, K89; K90) and periphery arterial disease (K92).

AMI, acute myocardial infarction; CV, cardiovascular; eGFR, estimated glomerular filtration rate.

[Table 2](#T2){ref-type="table"} provides an overview of eGFR slope and CV event during follow-up. Nearly 12% of the patients in the category ≤−5 and (−5 to −3) had a new CV event compared with 7.8% of the reference group. In the (3 to 5) and ≥5 group, a new event occurred only in about 6% of patients. [Figure 1](#F1){ref-type="fig"} displays the results of differences in survival time between patients belonging to any of previously defined slope groups. Also, an informative risk set table is added, which shows the number of patients who were under observation in the specific period. The risk table is indicative of how many people were available (or at risk) throughout this period. It appeared that those who had a slope ≥5 had the best survival rate. Less than 10% suffered from CV event during the time of follow-up. The patients who had a slope (−1 to 1, 1 to 3 and 3 to 5) had similar survival rates, but worse than those with a slope ≥5.00. Next were the patients with slope (−3 to −1), followed by (−5 to −3) and the worst survival rates were those with a slope ≤−5. Approximately 15% of the patients in slope category ≤−5 had a CV event in comparison to the reference group, where only 10% had an event.

![Estimates of survival probability in different years grouped by the 'slope categories' and risk set table with number of patients at risk per year.](bmjopen-2018-023594f01){#F1}

###### 

Number of patients with a cardiovascular (CV) event and mean number of events, stratified to estimated glomerular filtration rate (eGFR) slope in follow-up period

  eGFR slope                      ≤−5.00       (−5.00, --3.00)   (−3.00, --1.00)   (−1.00, 1.00)   (1.00, 3.00)   (3.00, 5.00)   ≥5.00
  ------------------------------- ------------ ----------------- ----------------- --------------- -------------- -------------- -----------
  No of patients with CV events   192 (12.0)   160 (11.2)        272 (9.7)         292 (7.8)       249 (6.9)      175 (6.3)      193 (5.4)
  Absolute no of CV events        225          173               302               319             278            187            216

An overview of the HRs and 95% CI per adjusted model stratified to eGFR slope is given in [table 3](#T3){ref-type="table"}. The HRs of patients with a positive eGFR slope were all insignificant, whereas the HRs of the negative eGFR slopes were statistically significant. Patients who had a slope ≤−5.00 were 1.55 more likely to develop a CV event compared with those of (−1.00, 1.00). Similar interpretations hold for the other groups as well. The adjusted HR increased with a declining negative eGFR slope, for example, model 2; 1.19, 1.37 to 1.55. Adjusting for comorbidity (hypertension, diabetes and CV event in history) attenuated the HR per category, while HR still remained significant for the negative eGFR slopes. Adjusting for baseline kidney function of the last measurement (model 3) did not affect the HRs of model 2, indicating that this covariate was insignificant.

###### 

Risk of an incident CV event during follow-up, HRs and 95% CIs per eGFR slope category (in mL/min/year)

  eGFR slope     ≤−5.00                (−5.00, --3.00)       (−3.00, --1.00)       (−1.00, 1.00)   (1.00, 3.00)          (3.00, 5.00)          ≥5.00
  -------------- --------------------- --------------------- --------------------- --------------- --------------------- --------------------- ---------------------
  HR model 1\*   1.68 (1.40 to 2.02)   1.44 (1.19 to 1.75)   1.20 (1.02 to 1.42)   1.00            0.96 (0.81 to 1.14)   0.99 (0.82 to 1.19)   0.93 (0.78 to 1.12)
  HR model 2†    1.55 (1.29 to 1.87)   1.37 (1.13 to 1.67)   1.19 (1.01 to 1.40)   1.00            0.99 (0.84 to 1.18)   1.02 (0.85 to 1.24)   1.00 (0.84 to 1.21)
  HR model 3‡    1.56 (1.29 to 1.87)   1.38 (1.13 to 1.67)   1.19 (1.01 to 1.41)   1.00            0.99 (0.84 to 1.17)   1.02 (0.84 to 1.23)   0.99 (0.82 to 1.21)

\*Adjusted for age and gender.

†Adjusted for age, gender, hypertension, diabetes and CV event history.

‡Adjusted for age, gender, hypertension, diabetes, CV event history and baseline kidney function (here is the last measurement).

CV, cardiovascular; eGFR, estimated glomerular filtration rate.

Discussion {#s4}
==========

eGFR slope and CV events: principal findings {#s4a}
--------------------------------------------

We used a large population to examine if a declining eGFR slope over a 5-year period can show subsequent worse CV outcome in the following 5 years. We found that patients with declining eGFR slope were more at risk of a CV event than those with stable or rising eGFR slope. The survival rates of patients with an eGFR slope ≤−3.00 mL/min/year were worse than the survival rates in other groups. These data suggest that the eGFR slope can be prognostic for CV health irrespective of the eGFR itself. Using eGFR slope can identify a group of patients with a still normal or slightly decreased eGFR and still higher risk for CV events.

Context of the results {#s4b}
----------------------

As to CV disease and eGFR slope, two recent studies with a large study population have been conducted. Naimark *et al* [@R12] found in a large analysis of several existing cohort studies that eGFR changes, positive as well as negative, have a significant association with all-cause mortality, CV mortality and non-CV mortality. Turin *et al* investigated the association between eGFR change over 2.5 years and the risk of congestive heart failure (CHF), AMI and stroke.[@R16] Risk of CHF, AMI and stroke was highest when eGFR decline was more than −5 mL/min/year. The adjusted HRs of CHF, AMI and stroke were 2.57, 1.31 and 1.29, respectively. However, when adjusting for last eGFR measurement, a significant association was only seen with CHF (HR: 1.78).

When we adjusted for the last eGFR measurement, no significant difference in HR was seen, in contrast to the Turin study, which used a shorter time period and only three eGFR measurements. We did not find a U-shape relation between the eGFR slope and CV events as reported for the eGFR slope and mortality.

An important finding in this study is that an eGFR slope \<−3 mL/min/year over a 5-year time period based on at least four eGFR measurement predicts CV event independent of the eGFR itself. Moreover, most of our patients with a negative eGFR slope still have an eGFR above 60 mL/min. Hence, this eGFR slope identifies a risk group that cannot be identified using the eGFR only.

Strengths and limitations {#s4c}
-------------------------

The strength of this study is that we used a large population with four eGFR measurements in different time periods, representative of the general population. Another strong point is that we collected these data over 10 years using the first 5 years as predictor for the next 5 years. Other studies often used a shorter time period for gaining eGFR values or fewer eGFR values to calculate their slope, causing the result to be more sensitive to smaller eGFR variations.

Our study is limited in that we did not have sufficient information about proteinuria, smoking and body mass index to use it in the analyses without resulting in considerable bias. Finally, using a real-life dataset means that there is an important loss to follow-up due to the combination of mortality and change of GP.

Recommendations {#s4d}
---------------

We think it is useful to implement the eGFR slope into medical software programs and create an alert to warn the GP when a declining eGFR of at least 3 mL/min/year is noticed and the patient is thus at risk of CV events. Implementing such an alert would contribute to the awareness of the GP more than personal intuition can do. The fact that most of the slope category ≤−5.00 had a normal kidney function at baseline is misleading and therefore deterioration of the eGFR slope can be underestimated if the eGFR slope is not taken into account.

To conclude, there is a correlation between eGFR slope over a 5-year time period and subsequent incident CV events. Negative eGFR slopes of at least---3.00 mL/min/year predict a higher risk of CV events over a 5-year period than stable slopes or increasing slopes independently of the eGFR at baseline. Further research is needed to study if this deterioration responds to treatment and if so, which treatments or preventive measures should be taken. It remains to be investigated whether slowing down the process of declining kidney function also diminishes the incidence of CV events. For these reasons, an intervention study is needed that will assess these questions.
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